Would you be more inclined to offer adjuvant therapy to a patient who is age>60 with stage 1B seminoma?   

Adjuvant therapy to reduce the risk of recurrence if there is concern that the patient would not be eligible for Bleomycin (BEP3) on account of age, or tolerate all 4 cycles of treatment (EP4) if there were to be a relapse.